Assessments (licensed) 2025 onwards: ESR, Recommendation and EqHIA

15/09/2026
Recommendation and Decision Rationale: adrenaline (EURneffy) 6284
15/09/2026
Evidence Summary Report: adrenaline (EURneffy) 6284
23/07/2026
Equality and Health Impact Assessment: adrenaline (EURneffy) 6284
26/05/2026
Evidence Summary Report: emicizumab (Hemlibra) 4742
26/05/2026
Recommendation and Decision Rationale: budesonide (Jorveza) 4507
26/05/2026
Equality and Health Impact Assessment: emicizumab (Hemlibra) 4742
26/05/2026
Evidence Summary Report: budesonide (Jorveza) 4507
26/05/2026
Equality and Health Impact Assessment: budesonide (Jorveza) 4507
26/05/2026
Recommendation and Decision Rationale: emicizumab (Hemlibra) 4742
26/05/2026
Equality and Health Impact Assessment: progesterone (Prometrium) 6820
26/05/2026
Evidence Summary Report: progesterone (Prometrium) 6820
26/05/2026
Recommendation and Decision Rationale: progesterone (Prometrium) 6820
20/06/2025
Evidence Summary Report: teriparatide 6561
20/06/2025
Equality and Health Impact Assessment: teriparatide 6561
20/06/2025
Recommendation and Decision Rationale: teriparatide 6561
29/05/2025
Recommendation and Decision Rationale: abiraterone 6441
29/05/2025
Equality and Health Impact Assessment: abiraterone 6441
29/05/2025
Evidence Summary Report: abiraterone 6441
29/05/2025
Recommendation and Decision Rationale: guanfacine (Intuniv) 6440
29/05/2025
Equality Health Impact Assessment: guanfacine (Intuniv) 6440